Form 4: Veracyte CEO Marc Stapley Executes $6.9M Stock Sale

Veracyte CEO Marc Stapley exercised options and sold 138,051 shares under a pre-arranged trading plan.

Summary

• Chief Executive Officer Marc Stapley exercised stock options for 138,051 shares of common stock at a price of $36.60 per share on June 4, 2026.
• Following the exercise, Stapley sold all 138,051 shares at a weighted average price of $50.1234, with individual sale prices ranging from $50.00 to $50.52.
• On June 2, 2026, 9,012 shares were withheld by the company to satisfy tax obligations related to the vesting of restricted stock units at a price of $47.80.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on November 24, 2025.
• A correction was noted regarding an administrative error from a September 2025 filing, where ESPP shares were overreported by 147 shares.
• After these transactions, Marc Stapley directly owns 440,494 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While the CEO sold a significant amount of stock, it was done through a pre-established plan and he remains a major shareholder.

Positives

• The CEO maintains a substantial direct ownership stake of 440,494 shares, aligning interests with shareholders.
• Transactions were executed under a Rule 10b5-1 plan, providing transparency and reducing concerns regarding opportunistic insider trading.
• The stock was sold at a significant premium ($50.12) relative to the option exercise price ($36.60).

Negatives

• The sale of 138,051 shares represents a total liquidation of the options exercised, which could be perceived as a lack of confidence in immediate further upside.
• An administrative error in previous filings led to the overreporting of shares held by the CEO for several months.

Risks

• Market perception of large-scale executive selling can lead to short-term downward pressure on the stock price.
• Potential for future volatility if other executives follow suit with similar 10b5-1 plan executions.

Future Outlook

The filing does not provide specific forward-looking guidance; however, the use of a 10b5-1 plan indicates a structured approach to executive liquidity that is planned months in advance.

Management Comments

• The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.
• Due to an administrative error, shares of common stock acquired... were incorrectly reported as 529 shares instead of 382 shares.

Industry Context

StockSavvy.ai notes that in the biotechnology and diagnostics sector, it is common for executives to utilize 10b5-1 plans to diversify their portfolios, especially when options are fully vested and nearing expiration.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard best practice for C-suite executives at NASDAQ-listed companies like Veracyte to avoid insider trading allegations.
• The CEO's retention of over 440,000 shares is consistent with high-level ownership requirements seen at peer companies such as Exact Sciences or Guardant Health.

Corporate Governance

Stakeholder Impact

• Shareholders may see increased trading volume in VCYT stock due to the 138,051 shares sold in the open market.

Next Steps

• Monitor future Form 4 filings for other executives to see if similar 10b5-1 plans are being triggered.

Key Dates

Recommendation

The insider activity is routine and pre-planned, suggesting no immediate change in the company's fundamental value or strategic direction.

Keywords

Veracyte, VCYT, Marc Stapley, Insider Trading, Form 4, Stock Options, Rule 10b5-1, CEO Stock Sale, Executive Compensation